ABBV AbbVie Inc RESULTS: Q2, Q2 global Skyrizi REV $5.505B, Q2 global Rinvoq REV $2.525B, Q2 global Humira REV $756M, Q2 ADJ EPS $3.65 vs. E

ABBV AbbVie Inc RESULTS: Q2, Q2 global Skyrizi REV $5.505B, Q2 global Rinvoq REV $2.525B, Q2 global Humira REV $756M, Q2 ADJ EPS $3.65 vs. EST $3.60, Q2 REV $16.990B vs. EST $16.765B, Abbvie Inc Earnings Notes:, Q2 results include an unfavorable impact of $0.17/share related to acquired ipr&d and milestones expense, FY 2026 ADJ EPS guidance includes $0.14 /share dilutive impact related to acquisition of Apogee Therapeutics